15 results match your criteria: "Paris 7-Paris Diderot University[Affiliation]"
Bone Marrow Transplant
July 2023
Josep Carreras Foundation & Leukemia Research Institute, (Hospital Clínic/Barcelona University Campus), Barcelona, Spain.
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). A new definition for diagnosis, and a severity grading system for SOS/VOD in adult patients, was reported a few years ago on behalf of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this work is to update knowledge regarding diagnosis and severity assessment of SOS/VOD in adult patients, and also its pathophysiology and treatment.
View Article and Find Full Text PDFTranspl Int
July 2020
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Hospital Regensburg, Regensburg, Germany.
Pediatric allogeneic hematopoietic cell transplantation (HCT) practices differ from those of adults, particularly the heterogeneity of transplantable nonmalignant diseases and the lower incidence of graft-versus-host disease (GVHD). Several guidelines regarding the management of acute (a) GVHD in adult HCT have been published. We aimed to capture the real-life approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/193 (response rate 39%) EBMT centers (26 countries) were included, representing half (48%) of the pediatric EBMT-HCT activity.
View Article and Find Full Text PDFCrit Care
December 2019
UMR 1137, IAME, Université Paris Diderot, F75018, Paris, France.
Bone Marrow Transplant
March 2020
Hematology Department, Josep Carreras Foundation and Leukemia Research Institute, Hospital Clínic, Barcelona, Spain.
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). While SOS/VOD may resolve within a few weeks in the majority of patients with mild-to-moderate disease, the most severe forms result in multiorgan dysfunction and are associated with a high mortality rate (>80%). Therefore, careful surveillance may allow early detection of SOS/VOD, particularly as the licensed available drug is proven to be effective and reduce mortality.
View Article and Find Full Text PDFIntensive Care Med
January 2020
Medical ICU, AP-HP, Saint Louis Hospital, Paris-7 Paris-Diderot University, Paris, France.
Biol Blood Marrow Transplant
April 2018
Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco; Hopital Saint Antoine, Service d'Hématologie et thérapie cellulaire, Paris, France.
Body mass index (BMI) may influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients age 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015.
View Article and Find Full Text PDFBone Marrow Transplant
February 2018
Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt/Main, Germany.
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate >80%.
View Article and Find Full Text PDFBone Marrow Transplant
July 2016
Josep Carreras Foundation & Leukemia Research Institute, Hematology Department, Hospital Clínic, Barcelona, Spain.
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment.
View Article and Find Full Text PDFBone Marrow Transplant
June 2015
1] Josep Carreras Leukaemia Research Institute, Barcelona, Spain [2] Haematology Department, Hospital Clinic, Barcelona, Spain [3] Spanish Bone Marrow Donor Program, Josep Carreras Foundation, Barcelona, Spain.
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation, the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Our perspectives on SOS/VOD are (i) to accurately identify its risk factors; (ii) to define new criteria for its diagnosis; (iii) to search for SOS/VOD biomarkers and (iv) to propose prospective studies evaluating SOS/VOD prevention and treatment in adults and children.
View Article and Find Full Text PDFBone Marrow Transplant
February 2014
Department of Hematology and Immunology, Hospital Robert Debre, Paris 7-Paris Diderot University, Paris, France.
Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines.
View Article and Find Full Text PDFEur J Anaesthesiol
January 2011
Department of Anaesthesia and Intensive Care, Beaujon University Hospital, Assistance Publique des Hôpitaux de Paris, Clichy, Paris 7 Paris Diderot University, INSERM U 676, Paris, France.
Dexmedetomidine is a potent alpha-2-adrenergic agonist, more selective than clonidine, with widespread actions on the mammalian brain that include sedation, anaesthetic-sparing, analgesia and sympatholytic properties. A large body of recent work supports its favourable profile in improving outcome and long-term brain function in the critically ill. The source of these benefits may lie in the neuroprotective properties that are seen in experimental models and in the clinical setting, in which it can attenuate delirium, preserve sleep architecture, preserve ventilatory drive and decrease sympathetic tone and inflammatory response.
View Article and Find Full Text PDFAnesthesiology
February 2010
Department of Anesthesia and Pain Management, INSERM U 676, Robert Debré University Hospital, Paris 7 Paris Diderot University, 48 Boulevard Sérurier, Paris, France.
Background: There is an increasing interest in the use of dexmedetomidine for anesthesia and sedation. Here, we used the mouse organotypic hippocampal slice culture to investigate whether dexmedetomidine exhibits postconditioning properties against oxygen and glucose deprivation (OGD). The role of the focal adhesion and extracellular-regulated kinases pathways in these effects were examined in both postconditioning and preconditioning.
View Article and Find Full Text PDFCurr Opin Anaesthesiol
April 2010
Department of Anesthesiology and Critical Care, Beaujon University Hospital, Paris 7 Paris Diderot University, Clichy, France.
Purpose Of Review: The present review examines the trends and controversies on how perioperative care can influence outcome after anesthesia and surgery.
Recent Findings: Recent studies indicate that anesthesia and perioperative care may have a major impact on long-term postoperative mortality and major complications in surgical patients by decreasing the rate of individual decisions. The use of a surgical checklist in the operating room improves postoperative mortality by decreasing the rate of individual decisions and facilitating communication between anesthesiologists, surgeons and intensivists.
Anesthesiology
January 2010
Beaujon University Hospital, Paris 7 Paris-Diderot University, and INSERM U 676, Paris, France.